Hyperbare Zuurstoftherapie: Rapid Assessment - KCE

KCE Reports 74 Hyperbaric Oxygenation Therapy 96
94. Rychlik R. Cost-effectiveness-relation of the treatment of diabetic foot lesion with hyperbaric
oxygen therapy versus standard therapy.159-64.
95. Marroni S, Longobardi P, Cali-Corleo R. A cost-benefit evaluation of hyperbaric oxygen
treatment of the diabetic foot.151-7.
96. Mulla ZD, Gibbs SG, Aronoff DM. Correlates of length of stay, cost of care, and mortality
among patients hospitalized for necrotizing fasciitis. Epidemiology and Infection.
97.
2007;135(5):868-76.
Ragnarson Tennvall G, Apelqvist J. Health-related quality of life in patients with diabetes
mellitus and foot ulcers. J Diabetes Complications. 2000;14(5):235-41.
98. Faglia E, Favales F, Aldeghi A, Calia P, Quarantiello A, Oriani G, et al. Adjunctive systemic
hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer. A
randomized study. Diabetes care. 1996;19(12):1338-43.
99. Doctor N, Pandya S, Supe A. Hyperbaric oxygen therapy in diabetic foot. Journal of
postgraduate medicine. 1992;38(3):112-4.
100. Baroni G, Porro T, Faglia E, Pizzi G, Mastropasqua A, Oriani G, et al. Hyperbaric oxygen in
diabetic gangrene treatment. Diabetes Care. 1987;10(1):81-6.
101. Zamboni WA, Wong HP, Stephenson LL, Pfeifer MA. Evaluation of hyperbaric oxygen for
diabetic wounds: a prospective study. Undersea Hyperb Med. 1997;24(3):175-9.
102. Bild DE, Stevenson JM. Frequency of recording of diabetes on U.S. death certificates: analysis of
the 1986 National Mortality Followback Survey. J Clin Epidemiol. 1992;45(3):275-81.
103. Baddeley RM, Fulford JC. A Trial of Conservative Amputations for Lesions of the Feet in
Diabetes Mellitus. Br J Surg. 1965;52:38-43.
104. Arias E National Vital Statistics Report;c 2002 [cited February 11, 2003]. United States life
table 2000, Center for Disease Control. Available from:
105.
http://www.cdc.gov/nchs/data/nvsr/nvsr51/nvsr51_03.pdf
Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort
of the U.S. population, 1971-1993. Diabetes Care. 1998;21(7):1138-45.
106. Ragnarson Tennvall G, Apelqvist J. Health-economic consequences of diabetic foot lesions. Clin
Infect Dis. 2004;39 Suppl 2:S132-9.
107. Faglia E, Favales F, Aldeghi A, Calia P, Quarantiello A, Barbano P, et al. Change in major
amputation rate in a center dedicated to diabetic foot care during the 1980s: prognostic
determinants for major amputation. J Diabetes Complications. 1998;12(2):96-102.
108. Kalani M, Jörneskog G, Naderi N, Lind F, Brismar K. Hyperbaric oxygen (HBO) therapy in
treatment of diabetic foot ulcers. Long-term follow-up. Journal of diabetes and its
complications. 2002;16(2):153-8.
109. Eckman MH, Greenfield S, Mackey WC, Wong JB, Kaplan S, Sullivan L, et al. Foot infections in
diabetic patients. Decision and cost-effectiveness analyses. JAMA. 1995;273(9):712-20.
110. Alberta Health & Wellness. Health trends in Alberta: A working document. 1999. Edmonton:
Government of Alberta Available from:
http://www.health.gov.ab.ca/resources/publications/trends_2000.pdf
111. Wunderlich RP, Peters EJ, Lavery LA. Systemic hyperbaric oxygen therapy: lower-extremity
wound healing and the diabetic foot. Diabetes Care. 2000;23(10):1551-5.
112. Brown DR, Davis NL, Lepawsky M, Cunningham J, Kortbeek J. A multicenter review of the
treatment of major truncal necrotizing infections with and without hyperbaric oxygen therapy.
Am J Surg. 1994;167(5):485-9.
113. Riseman JA, Zamboni WA, Curtis A, Graham DR, Konrad HR, Ross DS. Hyperbaric oxygen
therapy for necrotizing fasciitis reduces mortality and the need for debridements. Surgery.
1990;108(5):847-50.